Abstracts tagged "treatment"

Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting
First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial
Frank Behrens¹, Mikkel Ostergaard², Rumen Stoilov³, Piotr Wiland⁴, Thomas W. Huizinga⁵, Vadym Y. Berenfus⁶, Paul-Peter Tak⁷, Stoyanka Vladeva⁸, Juergen Rech⁹, Andrea Rubbert-Roth¹⁰, Mariusz Korkosz¹¹, Dmitriy Rekalov¹², Igor A. Zupanets¹³, Bo J. Ejbjerg¹⁴, Jens Geiseler¹⁵, Julia Fresenius¹⁵, Roman P. Korolkiewicz¹⁶, Arndt J. Schottelius¹⁶ and Harald Burkhardt¹, ¹CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, ²Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ³Clinic of rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, ⁴Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Occupational Diseases, Regional Clinical Hospital, Donetsk, Ukraine, ⁷Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, ⁸Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, ⁹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Internal Medicine I, University of Cologne, Cologne, Germany, ¹¹Malopolskie Centrum Medyczne, Krakow, Poland, ¹²Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, ¹³Clinical and Diagnostics Centre of National Pharmaceutical University MOH of Ukraine, Kharkiv, Ukraine, ¹⁴Slagelse Sygehus, Slagelse, Denmark, ¹⁵Asklepios Clinic Munich-Gauting, Gauting, Germany, ¹⁶Development, MorphoSys AG, Martinsried/Planegg, Germany
Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…
Abstract Number: 2546 • 2012 ACR/ARHP Annual Meeting
Tofacitinib Inhibits Radiographic Progression in Patients with Rheumatoid Arthritis Prone to Develop Structural Damage: A Post-Hoc Analysis of a Phase 3 Trial
Désirée van der Heijde¹, Robert B. M. Landewé² and David Gruben³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ³Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In the ORAL Scan trial…
Abstract Number: 1559 • 2012 ACR/ARHP Annual Meeting
Treatment Outcomes From a Nurse-Led Rheumatology Clinic in Monitoring of anti-TNF Therapy – a Randomised Controlled Trial
Ingrid Larsson¹, Bengt Fridlund¹, Barbro Arvidsson², Annika Teleman³ and Stefan Bergman⁴, ¹Jönköping University, Jönköping, School of Health Sciences, Jönköping University, Jönköping, Sweden, ²Halmstad University, School of Social and Health Sciences, Halmstad University, Halmstad, Sweden, ³Spenshults Hosp of Rheum Dis, Oskarstrom, Sweden, ⁴Spenshult Hospital, R&D Center, Spenshult Hospital, Oskarström, Sweden
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) treated with anti-TNF therapy are usually followed up by rheumatologists. Nurse-led rheumatology clinics have been proposed for patients…
Abstract Number: 1274 • 2012 ACR/ARHP Annual Meeting
Relationship Between Morning Stiffness Duration and Severity, Pain Intensity, and Measures of Disease Activity in a 12 Week Efficacy Study of a Modified (Delayed-Release) Prednisone Plus Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Frank Buttgereit¹, John R. Kirwan², Kenneth G. Saag³, Reike Alten⁴, Amy Grahn⁵, Patricia Rice⁶ and Maarten Boers⁷, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ³Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁴Charité Univ Medicine, Berlin, Germany, ⁵Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁶Statistics, CliniRx Research, Naperville, IL, ⁷Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: RA patients typically present with pain and morning stiffness (MS). MS is predictive of both functional disability and escalated RA care, but the best…
Abstract Number: 452 • 2012 ACR/ARHP Annual Meeting
Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose
Daniele F. Pereira¹, Rita N.V. Furtado², Natalia P. Machado³ and Jamil Natour⁴, ¹Disciplina de Reumatologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Disciplina de Reumatologia, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The optimal dose of corticosteroid to be used in intraarticular injection is not well established. The objective of this study is to compare the…
Abstract Number: L12 • 2012 ACR/ARHP Annual Meeting
Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies
G. Burmester¹, Ricardo Blanco², Andrea Rubbert-Roth³, Thijs Hendrikx⁴, Kenneth Kwok⁵, John Bradley⁶, Samuel H. Zwillich⁶, Birgitta Benda⁷ and Charles A. Mebus⁶, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²Rheumatology, Hospital Universitario Marques De Valdecilla, Santander, Spain, ³Internal Medicine I, University of Cologne, Cologne, Germany, ⁴Pfizer bv, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc., Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis (RA). The efficacy and safety…
Abstract Number: 2510 • 2012 ACR/ARHP Annual Meeting
Patient and Provider Factors Associated with Compliance with Rheumatoid Arthritis Treatment Recommendations
Leslie R. Harrold¹, George W. Reed², Katherine C. Saunders³, Ying Shan¹, Tanya Spruill⁴ and Jeffrey D. Greenberg⁵, ¹Dept of Medicine, UMass Medical School, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Center for Healthful Behavior Change, Department of Population Health, NYU School of Medicine, New York, NY, ⁵New York Hospital for Joint Disease, New York, NY
Background/Purpose: Only approximately 50% of rheumatoid arthritis (RA) patient with active disease receive care consistent with the American College of Rheumatology (ACR) recommendations for the…
Abstract Number: 1561 • 2012 ACR/ARHP Annual Meeting
Factors Influencing Implementation of Intensive Treatment Strategies for Early Rheumatoid Arthritis
Sabrina Meyfroidt¹, Diederik De Cock¹, Kristien Van der Elst², Laura van Hulst³, Marlies Hulscher³, Johan Joly⁴, Rene Westhovens⁵ and Patrick Verschueren⁵, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, ²Department of Development and Regeneration, Neuro-musculo-skeletal Research Unit, University Hospitals KULeuven, Leuven, Belgium, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ⁵Rheumatology, University Hospitals KULeuven, Leuven, Belgium
Background/Purpose: Despite the availability and demonstrated effectiveness of intensive treatment strategies for early rheumatoid arthritis (RA), a discrepancy seems to exist between theoretical acceptance and…
Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Bernd Raffeiner¹, Costantino Botsios², Francesca Ometto², Mariagrazia Canova², Livio Bernardi², Cristiana Vezzari², Silvano Todesco², Paolo Sfriso² and Leonardo Punzi², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…
Abstract Number: 465 • 2012 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Oral Methotrexate Versus Subcutaneous Methotrexate for the Treatment of Early Rheumatoid Arthritis
Glen S. Hazlewood¹, J. Carter Thorne², Janet E. Pope³, Gilles Boire⁴, Boulos Haraoui⁵, Carol A. Hitchon⁶, Edward Keystone⁷, Diane Tin⁸, CATCH Investigators⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Toronto, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: To determine the comparative effectiveness of subcutaneous (sc) versus oral methotrexate (MTX) as initial therapy for patients with early rheumatoid arthritis (ERA) in routine…
Abstract Number: 2486 • 2012 ACR/ARHP Annual Meeting
Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Eun Bong Lee¹, Roy Fleischmann², Stephen Hall³, Ronald F. van Vollenhoven⁴, John Bradley⁵, David Gruben⁶, Tamas Koncz⁷, Sriram Krishnaswami⁵, Gene Wallenstein⁶, Samuel H. Zwillich⁵, Bethanie E. Wilkinson⁶ and the ORAL Start Investigators⁸, ¹Seoul National University, Seoul, South Korea, ²Metroplex Clinical Research Center, Dallas, TX, ³Cabrini Medical Centre, Melbourne, Australia, ⁴Karolinska Institute, Stockholm, Sweden, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc., Groton, CT, ⁷Pfizer Inc., New York, NY, ⁸Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This Phase 3, 24-mo study (ORAL…
Abstract Number: 1568 • 2012 ACR/ARHP Annual Meeting
A Survey Study of Methotrexate Use by Rheumatologists and Their Patients with Rheumatoid Arthritis
Peter Nash¹ and Dave Nicholls², ¹University of Queensland, Brisbane, Australia, ²Coast Joint Care, Maroochydore, Australia
Background/Purpose: Methotrexate (MTX) is the anchor medication for the management of rheumatoid arthritis (RA); however there is limited patient-focused data available on the use of…
Abstract Number: 995 • 2012 ACR/ARHP Annual Meeting
Genetic Effects of HLA-DRB1, IL4R, and FcγRIIb On Long-Term Treatment Responses in Patients with Early Rheumatoid Arthritis: 78-Week Results of a Phase 4 Study
Alla Skapenko¹, Josef S. Smolen², Arthur Kavanaugh³, Vipin Arora⁴, Hartmut Kupper⁵ and Hendrik Schulze-Koops⁶, ¹Division of Rheumatology and Clinical Immunology, Med. Poliklinik,, University of Munich, Munich, Germany, ²Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ³UCSD School of Medicine, La Jolla, CA, ⁴Health Outcomes Research, Abbott, Abbott Park, IL, ⁵Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁶University of Munich, Munich, Germany
Background/Purpose: Previous analyses suggested that the HLA-DRB1 shared epitope (SE), and the IL4R V50I and the FcγRIIb I232T single nucleotide polymorphisms (SNPs) affected response to…
Abstract Number: 371 • 2012 ACR/ARHP Annual Meeting
Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis
Takahiko Sugihara¹, Tatsuro Ishizaki², Tadashi Hosoya¹, Shoko Iga¹, Waka Yokoyama¹, Fumio Hirano¹, Nobuyuki Miyasaka³ and Masayoshi Harigai⁴, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Treat-to-target is the consensus treatment strategy for patients with rheumatoid arthritis (RA), but supporting evidence for treat-to-target strategy in elderly RA patients in clinical…
Abstract Number: 2489 • 2012 ACR/ARHP Annual Meeting
Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634
Frédéric Vanhoutte¹, Minodora Mazur², Annegret Van der Aa¹, Piet Wigerinck¹ and Gerben van 't Klooster¹, ¹Galapagos NV, Mechelen, Belgium, ²Rheumatology, State Medical and Pharmaceutical University "Nicolae Testemitanu", Chisinau, Moldova
Background/Purpose: Janus kinases (JAKs) are critical components in signaling pathways for a number of cytokines and growth factors, including those involved in the disease process…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.